Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
Avalo Therapeutics reported positive topline results from the Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa, successfully meeting the primary HiSCR75 endpoint at both doses studied. The 150 mg and 300 mg doses demonstrated response rates of 42.2% and 42.9% respectively, compared to a 25.6% placebo rate, with statistically significant improvements observed in key secondary endpoints as well.
Key figures
- Drug Name
- Abdakibart (AVTX-009)
- Phase Of Trial
- Phase 2
- P value 150mg
- 0.018
- P value 300mg
- 0.015
- P value combined
- 0.004
- Patients enrolled
- 253
- Hiscr75 response 150mg
- 42.2%
- Hiscr75 response 300mg
- 42.9%
- Hiscr75 response placebo
- 25.6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.